Kainos Medicine Inc - Asset Resilience Ratio

Latest as of March 2025: 48.13%

Kainos Medicine Inc (284620) has an Asset Resilience Ratio of 48.13% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Kainos Medicine Inc to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

₩6.43 Billion

≈ $4.36 Million USD Cash + Short-term Investments

Total Assets

₩13.36 Billion

≈ $9.06 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2017–2024)

This chart shows how Kainos Medicine Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 284620 total asset value.

Liquid Assets Composition Over Time

This chart breaks down Kainos Medicine Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read debt load of Kainos Medicine Inc for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩6.43 Billion	48.13%
Short-term Investments	₩0.00	0%
Total Liquid Assets	₩6.43 Billion	48.13%

Asset Resilience Insights

Very High Liquidity: Kainos Medicine Inc maintains exceptional liquid asset reserves at 48.13% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Kainos Medicine Inc Industry Peers by Asset Resilience Ratio

Compare Kainos Medicine Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	2.50%
Dianthus Therapeutics Inc. NASDAQ:DNTH	Biotechnology	63.98%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	62.24%
Damora Therapeutics, Inc. NASDAQ:DMRA	Biotechnology	0.00%
Wecome Pharmaceutical Co Ltd SHE:300878	Biotechnology	0.67%
Tectonic Therapeutic, Inc. NASDAQ:TECX	Biotechnology	86.66%
Relmada Therapeutics Inc NASDAQ:RLMD	Biotechnology	95.25%
MediWound Ltd F:M8W	Biotechnology	56.04%

Annual Asset Resilience Ratio for Kainos Medicine Inc (2017–2024)

The table below shows the annual Asset Resilience Ratio data for Kainos Medicine Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	35.69%	₩3.83 Billion ≈ $2.60 Million	₩10.74 Billion ≈ $7.28 Million	-42.16pp
2023-12-31	77.85%	₩16.34 Billion ≈ $11.07 Million	₩20.99 Billion ≈ $14.22 Million	+1.02pp
2022-12-31	76.83%	₩29.95 Billion ≈ $20.30 Million	₩38.98 Billion ≈ $26.42 Million	-4.75pp
2021-12-31	81.59%	₩34.23 Billion ≈ $23.20 Million	₩41.96 Billion ≈ $28.43 Million	-4.13pp
2020-12-31	85.72%	₩29.81 Billion ≈ $20.20 Million	₩34.78 Billion ≈ $23.57 Million	-13.35pp
2019-12-31	99.07%	₩10.60 Billion ≈ $7.18 Million	₩10.70 Billion ≈ $7.25 Million	-0.06pp
2018-12-31	99.12%	₩10.51 Billion ≈ $7.12 Million	₩10.60 Billion ≈ $7.18 Million	-0.87pp
2017-12-31	100.00%	₩1.69 Billion ≈ $1.15 Million	₩1.69 Billion ≈ $1.15 Million	--

pp = percentage points

About Kainos Medicine Inc

KQ:284620 Korea Biotechnology

Market Cap

$24.10 Million

₩35.56 Billion KRW

Market Cap Rank

#24600 Global

#1768 in Korea

Share Price

₩1087.00

Change (1 day)

+0.00%

52-Week Range

₩1087.00 - ₩1087.00

All Time High

₩28151.21